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Background
Primary Sjögren’s Syndrome (pSS) is a chronic autoim-
mune syndrome characterised by sicca symptoms, fatigue,
musculoskeletal pain and an increased risk of lymphoma.
Patient populations are notably heterogeneous in their
symptoms, adding to the challenge of pSS research.
This study utilises serum samples from the UK Primary
Sjögren’s Syndrome Registry (UKPSSR) - a large cohort of
clinically well-characterised pSS patients and healthy con-
trols with an aim to determine whether serum cytokines,
chemokines and adhesion molecules may be used to dif-
ferentiate pSS patients from healthy controls.
Methods
Serum levels of 24 different analytes for 150 pSS patients
and 30 age matched healthy controls were measured using
Cytometric Bead Array (BD Biosciences).
The primary Sjögren’s Syndrome subjects (charac-
terised by AECG criteria) were stratified as follows:
• Lymphoma and/or paraprotein positive;
• High systemic disease activity (ESSDAI score > 12);
• High Fatigue (VAS score >85);
• Low residual glandular function (OSF <1 ml/15 min
and Schirmer’s test <1 cm)
The relationship between the levels of each analyte
and clinical and laboratory parameters of PSS was exam-
ined using multivariate analysis and Mann-Whitney U
testing; p-values were adjusted for multiple comparisons
using Bonferroni’s correction.
Results
There were marked differences in the levels of 11 ana-
lytes between pSS patients and healthy controls, with a
p value <0.001, statistically significant after Bonferroni’s
correction for multiple comparisons. However, none of
the serum factors measured significantly differentiate
different Sjögren’s subsets after multiple comparison
correction.
The violin-box plots in Figure 1 show the data distri-
bution. Most soluble molecules show an ‘hour-glass’ dis-
tribution, particularly within the patient group
corresponding to groups of patients with higher and
lower levels of analyte.
Discussion
Differences in blood cytokine and chemokine levels
between primary Sjögren’s Syndrome patients and controls
can be detected in serum through the use of Cytometric
Bead Arrays. 11 serum analytes differ significantly between
patients and controls: IP10 (CXCL10), IL17, IL21, IFNa,
MIP1a (CCL3), LTA and TNFa, MIP1b (CCL4), IFNa,
MIG (CXCL9), IL6 and IL10. Our observations raise the
possibility that these analytes may be important in disease
pathogenesis.
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